VIVITROL (naltrexone for extended-release injectable suspension) VIVITROL: A Treatment Option For The Daily Struggle Against Alcohol Dependence. One dose all month long.
Healthcare Professional Site
Prescribing Information
Send to a Friend
Homepage About Vivitrol Request Information SEARCH
About VIVITROL
My Path to Recovery
Overview


Mechanism of action


Efficacy


Dosage/Administration


Adherence


Safety Considerations


VIVITROL Preparation and Administration
What is VIP3?


How do I start a patient on therapy?

VIVITROL preparation and administration

Frequently asked questions

  • Can I prepare the suspension prior to my patient's arrival?

    No. You may remove the carton from the refrigerator prior to the patient's arrival, but once the diluent is added to the VIVITROL Microspheres, the dose should be mixed and the suspension administered immediately. It is very important to use proper aseptic technique when preparing the suspension. VIVITROL must be administered by a healthcare professional.

  • How much time do I have between preparing and administering the dose?

    It is recommended that the suspension be administered immediately once the product has been suspended and transferred into the syringe. If a few minutes' delay occurs after suspension but before transfer into the syringe, the vial can be inverted a few times to resuspend and then transferred into the syringe for immediate use.

  • Can I use needles or diluent other than those provided in the carton?

    VIVITROL must be suspended only in the diluent supplied in the carton and must be administered with the needle supplied in the carton. All components (ie, the microspheres, diluent, preparation needle, and an administration needle with safety device) are required for administration. A spare administration needle is provided in case of clogging. Do not substitute any other components for the components of the carton.

  • The suspension is milky white upon mixing with the diluent. Is this normal?

    Yes. VIVITROL Microspheres will form a milky white suspension when mixed with the provided diluent.

  • What if a needle clog occurs during administration of the product?

    If a clog occurs during administration, the needle should be withdrawn from the patient, capped with the attached safety device, and replaced with the spare administration needle provided. Gently push on the plunger until a bead of the suspension appears at the tip of the needle. The remainder of the suspension should then be administered into an adjacent site in the same gluteal region.

  • My patient missed an appointment. What do I do?

    If a patient misses a dose, he/she should be instructed to receive the next dose as soon as possible. There are no data to specifically address the reinitiation of treatment in a patient who has previously discontinued treatment.

Important Safety Information
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses. Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.